Immortalized Intestinal Epithelial Cells via CDKN2A Inactivation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current research on intestinal epithelial cells is limited by the lack of physiologically relevant in vitro models, particularly 2D models that are reproducible and robust, with simultaneous apical and basolateral access, and the inability to develop genetically engineered intestinal cell lines.
Innovation Solution
A novel method for obtaining a homogenous population of colon epithelial crypts and intestinal epithelial cells, involving the isolation of crypts using a non-enzymatic cell recovery solution and Rho-kinase inhibitor, followed by immortalization of primary colon epithelial cells by inactivating the CDKN2A locus and expressing the hTERT transgene.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If primary intestinal epithelial cells are used for in vitro culture, then physiological relevance is improved, but culture duration is limited due to short survival
Solution Approach 1:
The patent applies preliminary action by pre-inactivating the CDKN2A locus and introducing the hTERT transgene into primary intestinal epithelial cells before culture establishment. This genetic modification is performed in advance to prevent senescence and enable long-term culture, resolving the contradiction between maintaining physiological relevance and extending culture duration.
2Duration of action of moving object
If 3D organoid culture methods are used, then long-term culture capability is improved, but operational complexity increases
Solution Approach 1:
The patent extracts the essential function of long-term culture capability from the complex 3D organoid system by applying genetic modification (CDKN2A inactivation and hTERT introduction) to primary cells. This allows establishment of simplified 2D monolayer cultures that inherit the long-term culture capability without requiring complex 3D culture conditions, imaging, or quantification methods.
Solution Approach 2:
The patent creates a simplified copy of the long-term culture capability achieved in 3D organoids by transferring the essential genetic modifications to primary intestinal epithelial cells. This produces a 2D monolayer model that replicates the extended culture duration and self-renewal properties without needing the complex 3D hydrogel environment.
3Ease of manufacture
If tumour-derived cell lines are used, then ease of maintenance is improved, but physiological accuracy deteriorates
Solution Approach 1:
The patent applies preliminary action by performing genetic modification (CDKN2A inactivation and hTERT introduction) on primary intestinal epithelial cells before establishing culture. This allows the cells to acquire immortalization properties similar to tumour cell lines, enabling easy long-term maintenance while preserving the physiological characteristics of normal epithelial cells.
Data Source
Figure 1
Figure 2
Figure 3A~3B
AI summary
The present invention provides a novel method for obtaining a homogenous population of mammalian colon epithelial crypts, as well as a homogenous population of intestinal epithelial cells. The present invention provides a novel method for immortalization of primary colon epithelial cells by inactivation of the CDKN2A locus and expression of human telomerase reverse transcriptase (hTERT) transgene. This method can be used for digestive system fundamental research, disease modelling and drug screening.